摘要
目的探讨卵巢癌患者血清α-羟丁酸脱氢酶、糖类抗原125(CA125)在卵巢癌中的表达情况,分析二者联合检测对卵巢癌的诊断价值。方法选取40例卵巢癌患者、35例卵巢良性病变患者和40例健康者,分别命名为卵巢癌组、卵巢良性病变组、健康对照组。检测血清α-羟丁酸脱氢酶、CA125水平,探讨血清α-羟丁酸脱氢酶水平与卵巢癌患者病理特征的关系。绘制受试者工作特征(ROC)曲线,分析血清α-羟丁酸脱氢酶联合CA125检测对卵巢癌的诊断效能。结果卵巢癌组和卵巢良性病变组患者的血清CA125、α-羟丁酸脱氢酶水平均高于健康对照组受试者,卵巢癌组患者的血清CA125水平高于卵巢良性病变组患者(P﹤0.05)。不同分化程度、国际妇产科联盟(FIGO)分期和淋巴结转移情况的卵巢癌患者的血清α-羟丁酸脱氢酶水平比较,差异均有统计学意义(P﹤0.01)。ROC曲线分析结果显示,血清α-羟丁酸脱氢酶联合CA125检测鉴别诊断卵巢癌与卵巢良性病变的曲线下面积为0.834(95%CI:0.743~0.924),灵敏度和特异度分别为85.46%和90.02%;鉴别诊断卵巢癌与健康者的曲线下面积为0.958(95%CI:0.919~0.997),灵敏度和特异度分别为89.47%和95.83%。结论卵巢癌患者的血清α-羟丁酸脱氢酶和CA125水平较高,有一定的卵巢癌诊断价值,二者联合检测可提高对卵巢癌的诊断效能。
Objective To explore the serumα-hydroxybutyrate dehydrogenase and carbohydrate antigen 125(CA125)levels in patients with ovarian cancer,and to determine the clinical value of combined detection ofα-hydroxybutyrate dehydrogenase and CA125 in the diagnosis of ovarian cancer.Method A total of 40 patients with ovarian cancer,35 patients with benign ovarian disease and 40 healthy people were included in this study as ovarian cancer group,benign ovarian disease group and healthy control group,respectively.The serumα-hydroxybutyrate dehydrogenase and CA125 levels were detected in these subjects to investigate the relationship between serumα-hydroxybutyrate dehydrogenase levels and pathological characteristics of patients with ovarian cancer;receiver operating characteristic(ROC)curve was plotted to determine the diagnostic efficiency of serumα-hydroxybutyrate dehydrogenase combined with CA125 in the differential detection of ovarian cancer.Result The serum CA125 andα-hydroxybutyrate dehydrogenase levels in ovarian cancer group and the ovarian benign disease group were significantly higher than those in healthy control group,and the serum CA125 level in ovarian cancer group was also evidently higher than in ovarian benign disease group(P<0.05).The serumα-hydroxybutyrate dehydrogenase level in patients with ovarian cancer was related to the degree of tumor cell differentiation,International Federation of Gynecologyand Obstetrics(FIGO)stage and lymph node metastasis,with statistically significant difference observed(P<0.01).ROC curve analysis revealed that,the area under the curve(AUC)of serumα-hydroxybutyrate dehydrogenase combined with CA125 in the differential detection of ovarian cancer from benign ovarian disease was 0.834(95%CI:0.743-0.924),with sensitivity and specificity being 85.46%and 90.02%,respectively;the AUC of differential diagnosis between ovarian cancer and healthy control was 0.958(95%CI:0.919-0.997),the corresponding sensitivity and specificity were 89.47%and 95.83%,respectively.Conclusion The expression of serumα-hydroxybutyrate dehydrogenase and CA125 levels in patients with ovarian cancer arerelatively high,the combined detection of the two may further improve the diagnostic efficiency for ovarian cancer.
作者
李娇
樊冬梅
黄彦霞
LI Jiao;FAN Dongmei;HUANG Yanxia(Department of Gynecology and Obstetrics,the Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,He’nan,China)
出处
《癌症进展》
2020年第5期512-514,518,共4页
Oncology Progress
基金
河南省医学科技攻关计划联合共建项目(2018020173)。
关键词
Α-羟丁酸脱氢酶
糖类抗原125
卵巢癌
卵巢良性病变
受试者工作特征
α-hydroxybutyrate dehydrogenase
carbohydrate antigen 125
ovarian cancer
benign ovarian disease
receiver operating characteristic
